Our goal for 2026 is ambitious:
👉 To solve GTN leakage for the top global pharma manufacturers and recoup millions of dollars lost in patient affordability programs.
Protecting every patient enrolled and every dollar spent.
If we can achieve this, we can fundamentally change how high-cost, high-volume therapies reach patients across every major therapeutic area.
Making the omni-therapeutic landscape more integrated and accessible for patients—whether it’s oncology, immunology, neurology, or rare and chronic diseases—means working at scale.
Here’s how RIS Rx has risen to the occasion to accomplish this.
Over the past year, we’ve built the team and structure to scale while maintaining patient-first outcomes and a perfect NPS score.
In December, we launched solutions for 3 top 20 drug brands in one week.
We now have:
- An exceptional CRO Mark Bivins who’s driven valuable growth and shown impact from day one
- Co-founder Stephen Hom becoming COO to focus entirely on execution quality as demand accelerates
- A stellar marketing VP Chase Carpenter working with our incredible board to spread our belief that all dollars intended for patients must reach them
- Eric Reuland on the Ops team to optimize for any floods of inbound calls
- General Counsel, Jason Liljestrom, to remove friction and move faster to execute contracts
When I look at our office today, the thing I’m most proud of isn’t the growth—it’s the calm.
That tells me that not only is the foundation strong, access is working better for millions of patients.
The RIS Rx leadership team aligned around one mission: eliminate GTN leakage and ensure every dollar intended for patients reaches them.
